Samuraciclib hydrochloride hydrate

Samuraciclib (CT7001) hydrochloride hydrate is an orally bioavailable, ATP-competitive, and selective CDK7 inhibitor (IC50 = 41 nM) . It demonstrates potent anti-proliferative activity in breast cancer cell lines (GI50 0.2-0.3 μM) and has shown efficacy in vivo, supporting its investigation in oncology research, particularly for hormone receptor-positive breast cancer.